Cell transplantation after enclosing in microcapsules has been studied as an alternative approach for treatment of wide variety of diseases. In the present study, we examined the feasibility of using agarose microcapsules, having a cell-enclosing hollow core of 100-150 µm in diameter and agarose gel membrane of about 20 µm in thickness, as a device for the methodology. We enclosed cells that had been genetically engineered to express cytochrome P450 2B1, an enzyme that activates the anticancer prodrug ifosfamide. The enclosed cells were shown to express the enzymatic function in the microcapsules in that they suppressed the growth of tumor cells in medium containing ifosfamide. In addition, a more significant regression of preformed tumors was observed in the nude mice implanted with the cell-enclosing microcapsules compared with those implanted with empty capsules after administration of ifosfamide. Preformed tumors shrank by less than 40% in volume in 6 of the 10 recipients implanted with cell-enclosing microcapsules. In contrast, only 1 in 10 of the preformed tumors in the recipient implanted with empty microcapsules shrank by this amount. These results suggest that agarose microcapsules containing cytochrome P450 2B1 enzyme-expressing cells are feasible devices for improving the chemotherapy of tumors. Thus, agarose microcapsule having hollow cores are generally a good candidate as vehicles for cell-encapsulation approaches to cell therapy. 933 934 SAKAI ET AL.
INTRODUCTION
methods for enhancing immunoisolatability, biocompatibility, and mechanical stability (18, 27) .
Recently, we developed a novel technique for pro-Treatment of diseases by transplanting living cells or tissue fragments enclosed in spherical vehicles with ducing microcapsules of about 200 µm in diameter with hollow cores of 100-150 µm in diameter in which en-polymeric membranes has been studied since the 1960s (3), and its efficiency was revealed not only in animal closed cells grew and formed spheroid-like structures until they almost completely filled the hollow core (21). studies (1, 2, 12) but also in several clinical trials (8, 14, 15, 26) . Recent advances in genetic engineering enabling
The size of the microcapsules was smaller than those of conventional cell-enclosing microcapsules or vehicles of the use of cells as reactors to provide desired proteins have increased the applicability of the methodology to a 300-1,000 µm in diameter (18, 27) . Such small vehicles are attractive from the view points of molecular ex-wider range of diseases (4, 9) . Advances in the production of spherical devices or microcapsules as protective changeability, mechanical stability (22), and suppression of foreign body reaction to implanted vehicles (19, 25) . structures for implanted therapeutic cells also have improved the feasibility of the methodology. Over the past In addition, smaller vehicles are expected to reduce the surgical trauma for implanting cell-enclosing vehicles decade, a wide variety of spherical vehicles have been developed using a variety of materials and encapsulation because of the reduction in the size of the vehicles' in-jection device. Moreover, the size of hollow cores was Animals and Cells less than the allowable size of 150-200 µm in diameter Male nude mice (BALB/cA Jcl-nu, 8 weeks old) for multicellular spheroids that does not limit the oxygen were purchased from Kyudo (Saga, Japan). The animals supply, resulting in necrotic region formation inside the were housed in an isolator at 20°C. All the protocols tissues (5, 13) .
using the animals were according to the recommenda-Microcapsules consisting of an outer shell inside tions of Kyushu University entitled Guide for the Care which is a small hollow core containing mammalian and Use of Laboratory Animals. cells have not been reported, except for our recent re-Feline kidney cells engineered to produce the liver ports (20,21). We demonstrated the efficiency of this active enzyme CYP2B1 (16), an ifosfamide-activating technology in creating vehicles for the production of cytochrome (CYP2B1 cell), were grown in Dulbecco's spherical tissues such as embryoid body from embryonic modified Eagle's medium (DMEM, Sigma) containing stem cells in vitro. The purpose of this study is to evalu-10% fetal bovine serum (FBS), 400 mg/dl glucose, 75 ate the feasibility of using agarose microcapsules as cellmg/L penicillin, and 50 mg/L streptomycin. They were enclosing vehicles for cell therapy and we focus espeencapsulated in agarose microcapsules with hollow cially on the targeted treatment of tumors in this study.
cores. Human tongue squamous carcinoma cell line SAS Agarose is a natural polysaccharide extracted from the was used to establish tumors in nude mice. The cells cellular walls of agarophyte seaweed and exhibits temwere grown in RPMI-1640 medium containing the same perature-sensitive water solubility. Agarose gels have quantities of FBS, glucose, penicillin, and streptomycin been widely studied for biomedical applications includas those in the medium for CYP2B1 cells, respectively. ing spherical vehicles for allotransplantation due to a Both cells were cultured in a humidified atmosphere at high degree of biocompatibility (11) .
37°C with 5% CO 2 . In this study, we enclosed the cells genetically engineered to express cytochrome P450 2B1 (CYP2B1)
Cell Encapsulation into the hollow core of our novel agarose microcapsules. By implanting the microcapsules enclosing the Agarose microcapsules with hollow cores of about 100 µm in diameter and capsule membrane of about 20 cells into or close to tumors, we attempted to develop an alternative site of activation of prodrug, ifosfamide, µm in thickness were prepared based on a previously described method that has negligible effects on the via-which normally occurs in the liver. Ifosfamide is a prodrug that is specifically metabolized into two major ac-bility of mammalian cells and results in microcapsules with a single hollow core (21). Briefly, as a template of tive compounds, phosphoramide mustard and acrolein, by CYP2B1 in the liver (7) . Due to a very short half-the hollow core of microcapsules, CYP2B1 cell-enclosing spherical Alg-Ph particles of about 100 µm in diam-life of the activated compounds in plasma, ifosfamide has to be given in relatively high does despite severe eter were prepared via HRP-catalyzed enzymatic reaction by extruding 1.5% (w/v) Alg-Ph dissolved in side effects associated with such doses. One effective approach for reducing the side effects without lowering calcium-free Krebs Ringer HEPES-buffered solution (KRH, pH 7.4) into a laminar flow of liquid paraffin response rates involves the establishment of a second site of enzyme conversion near or in the tumor by dissolving H 2 O 2 (0.82 mmol/L) and lecithin (3.0%, w/w). The extruded Alg-Ph solution contained HRP and CRFK bringing cells transfected to express CYP2B1 close to tumor (14-16). cells at 1.7 U/ml and 1.5 × 10 7 cells/ml, respectively.
The emulsion system was collected in a 50-ml plastic tube and incubated for further 10 min to allow enzy-MATERIALS AND METHODS matic gelation. After being rinsed using KRH, resultant Materials cell-enclosing Alg-Ph microparticles were suspended in 4% (w/w) agarose in KRH maintained at 38°C. The sus-Agarose with a low gelling temperature (26-30°C at 1.5%) was purchased from Cambrex Bio Science Rock-pension was extruded into a coflowing stream of liquid paraffin containing lecithin (3.0%, w/w) but not H 2 O 2 . land (Rockland, ME, USA). Alginate containing 2.8 hydroxyl phenolic moieties per 100 repeat units of uronic
The resultant emulsion of ungelated agarose droplets containing Alg-Ph microparticles was collected in a 50-acid (Alg-Ph) was synthesized as reported previously (24) . Aqueous H 2 O 2 solution (31%, w/w) and liquid par-ml plastic tube and then cooled for 10 min in an ice bath for gelation of the agarose solution. The resultant affin were obtained form Kanto Kagaku (Tokyo, Japan). Lecithin from soybean and horse radish peroxidase microparticles were collected in KRH and rinsed several times with medium. Next, the microparticles were incu-(HRP; 170 U/mg) were obtained form Wako Chemicals (Osaka, Japan). bated in medium containing alginate lyase (0.2 mg/ml) for 1 h to liquefy the enclosed alginate microparticles RESULTS by enzymatic degradation. Growth profiles of the en-Cellular Growth in Microcapsules closed cells were estimated by increases in the amount
To determine the growth of the CYP2B1 cells in the of a water-soluble formazan dye, which was derived hollow core of agarose microcapsules of about 200 µm from a tetrazolium salt dissolved in medium containing in diameter, we measured transition of mitochondrial acsuspended cell-enclosing microcapsules, using a coloritivity of cells per microcapsules for estimating growth metric assay kit (Cell Counting Kit-8; Dojindo, Kumaof enclosed cells and observed changes in their morpholmoto, Japan).
ogy. The mitochondrial activity gradually increased with prolonged culturing (Fig. 1) , where 46.7-fold increase in Function of Enclosed CYP2B1 Cells In Vitro activity was achieved after 3 weeks of culturing compared to day 1. The area that the cells occupied in the The expression of biologically active CYP2B1 in the microcapsules increased with increasing culture period cells enclosed in hollow cores of agarose microcapsules ( Fig. 2a, b ). The cells existed individually in the microwas determined using a transwell system. SAS cells suscapsules immediately after preparation of microcapsules pended in medium were seeded at 2.5 × 10 4 cells/well in (Fig. 2a ) self-aggregated and formed cellular aggregates 12-well transwell dishes. After 4 h of incubation, the in hollow cores (Fig. 2b) . medium was changed to the medium containing ifosfam-
We also studied the potential ability of the enclosed ide at 1 mM and CYP2B1 cell-enclosing agarose microcells to grow in vivo by implanting the CYP2B1 cellcapsules were placed into a filter insert at 2.5 × 10 3 capcontaining agarose microcapsules into the peritoneal sules/well. The medium containing ifosfamide was changed cavities of nude mice. The microcapsules containing the to the fresh one containing ifosfamide at 1 mM at 24 h cells were recovered after 6 days of implantation by a of incubation. The number of SAS cells was counted peritoneal lavage with saline after the animals were sacfurther at 24 h of culture using a hemocytometer.
rificed under deep anesthesia with ether. As can be seen in Figure 2c , the cores of these capsules were filled with Treatment of Tumors cells. A comparison of the cells in the hollow core of SAS cells suspended in saline was injected subcutamicrocapsules grown in cell culture medium (Fig. 2b ) neous into the backs of nude mice (3.0 × 10 6 cells suswith those explanted from mice (Fig. 2c ) revealed that pended in 0.25 ml saline/animal) using a 26-gauge sythe latter grew faster. ringe. After 11 days of growth, the mice with tumors of CYP2B1 Activity Expression in Microcapsules >350 mm 3 were divided into two groups consisting of 10 animals each. The volumes of tumors were calculated Maintenance of expression of the enzymatic function based on the measurement of the greatest, a, and least, of CYP2B1 cells after encapsulation in the agarose mib, diameters of the tumors using the following standard crocapsules with hollow cores was determined by studyformula: volume = (a × b 2 ) × 0.5. The recipients of one group received CYP2B1 cells enclosed in agarose microcapsules (containing 3.0 × 10 5 cells) and the recipients of the other group served as a control and were implanted with the same number of microcapsules (1.0 × 10 4 microcapsules per recipient). The microcapsules were injected into each tumor after suspending in saline using a 22-gauge syringe. One day after the implantation, ifosfamide dissolved in saline was injected into the peritoneal cavities of the animals at 100 mg/kg body weight. The injection was done every 3 days for the first 9 days and then every 6 days until day 28. After the period, the mice were euthanized by an overdose of diethyl ether.
Statistical Analysis
Comparisons among groups were carried out using one-way ANOVA and the Bonferroni-corrected t-test. Values of p < 0.05 were considered to be significant. tured in the medium containing both ifosfamide and CYP2B1 cell-enclosing microcapsules showed a significant suppression of growth of the SAS cells (p < 0.05). The number of cells after 48 h of culture with both microcapsules and ifosfamide was 30% of those in the medium containing either of them alone (p < 0.05). Morphological differences between the cells (Fig. 3b-d) supported theses results. We could not find morphological differences between the cells in the media except for that containing both ifosfamide and cell-enclosing capsules where there were fewer cells attached to the culture dish and correspondingly more cell death.
Preformed Tumor Regression After Implanting Microcapsules
To investigate the effects of CYP2B1 expression from the enclosed cells in agarose microcapsules on ifosfamide treatment of preformed tumors, time course changes in volumes of the preformed tumors were measured. The tumor volumes in the recipients of cell-enclosing microcapsules decreased more significantly than those in the recipient of empty microcapsules (Fig. 4) . In the former group, the preformed tumors shrank by less than 20% volume in one recipient on day 6. The number of the recipients with tumors of less than 20% volume of the initial preformed tumors increased with increasing experimental period by day 15. On day 15, only one mouse had tumor of more than 60% volume of that of the preformed tumor. At the end of the experiment (i.e., at 28 days), 4 of 10 recipients implanted with cell-enclosing microcapsules had tumors of less than 20% volume of preformed tumors. In contrast, the degree of tumor regression was slower in the recipients implanted with empty microcapsules compared with those implanted with cell-enclosing microcapsules. On day 15, five recipients of empty microcapsules had tumors of more than 60% volume of preformed tumors. At the end of experiment, there were no recipients having the tumors less than 20% volume of preformed tumors. fied hollow cores of 100-150 µm in diameter as vehicles for treatment of diseases using the functions of enclosed cells. In this study, we examined the treatment of tumors ing the inhibition of growth of the SAS cells in the medium containing either ifosfamide or CYP2B1 cell-enclosing using small microcapsules. To accomplish our objective we encapsulated cells that had been genetically engi-microcapsules. The number of SAS cells cultured in the medium containing either of them increased to about neered to stably express CYP2B1. Implantation of the microcapsules into or close to tumor was expected to 4.5-fold after 48 h (Fig. 3a) , indicating that there were no significant differences in the number of cells cultured allow us to establish a second site for activating prodrugs for tumors that normally occurs in the liver, which in the media containing either ifosfamide or cell-enclosing microcapsules (p > 0.05). In contrast, the cells cul-is a major site for the expression of CYP2B1 as well as other cytochrome P450s (14). In a previous study, we drance of cellular growth and occurrence of drastic reduction of viability of the enclosed cells after 1 week of implanted CYP2B1 cells enclosed in agarose microparticles smaller than conventional cell-enclosing spherical encapsulation, due to microscopic stress forces from the surrounding agarose gel (10) . Orive and coworkers dem-vehicles but with solid cores to the mice with subcutaneous preformed tumors (23). Drawbacks to the use of onstrated the effectiveness of liquefaction of spherical vehicles' core for improving viability and antibody pro-these solid core agarose microparticles included hin-In this study, we first studied the growth of CYP2B1 cells enclosed in the hollow core of agarose microcapsules. As we have previously observed with the mouse embryonic stem cells enclosed in hollow cores of agarose microcapsules (21), we could detected growth of the encapsulated CYP2B1 cells in vitro (Figs. 1, 2a, b ). In addition, their growth was also demonstrated in vivo by collecting the implanted microcapsules from peritoneal cavity of animals ( Fig. 2c ). Comparing the cells at the same time point after encapsulation (i.e., 6 days), the cells in the microcapsules implanted in vivo grew faster than those cultured in vitro (Fig. 2b, c) . The faster growth of cells in vivo was interpreted as a consequence of the difference in the kind of nutrients and growth factors available in continuous supply to the enclosed cells in body fluids compared with cell culture medium, which become depleted. The cellular growth in the hollow cores of implanted microcapsules indicates the usefulness of the agarose microcapsules not only from the view points of biocompatibility and molecular exchangeability between the enclosed cells and surrounding environment resulting from smaller diameter compared with conventional cell-enclosing capsules but also prolongation of therapeutic effects in vivo.
DISCUSSION
Next, we studied the expression of CYP2B1 after encapsulation. The significant suppression of growth of SAS cells only in the medium containing both ifosfamide and cell-enclosing agarose microcapsules ( Fig. 3 ) clearly showed the expression of CYP2B1 in the cells enclosed in the microcapsules. We thus performed tumor regression study by implanting CYP2B1 cell-enclosing microcapsules into the mice with preformed tumors. The faster reduction of tumor volumes in the recipients implanted with CYP2B1 cell-enclosing microcapsules compared to those implanted with empty microcapsules under dosing ifosfamide (Fig. 4c ) showed that even in vivo the enclosed cells expressed CYP2B1, acting as an alternative site for activating ifosfamide. The slower but measurable reduction of tumor volumes even in the recipients of empty microcapsules can be explained by the endogenous activation of ifosfamide by the liver of these were placed into a suitable artery feeding a primary tumor. In contrast, the size of the microcapsules used in this study is smaller than the allowable size of multicellular spheroids that does not limit the oxygen supply, duction of enclosed cells (17). In our system, the cells initially enclosed in Alg-Ph microparticles were relieved resulting in necrotic region formation inside the tissues (5, 13) . Formation of a necrotic region inside spherical from the stresses from surrounding Alg-Ph gel by enzymatically liquefying the gel after the formation of agar-tissues enclosed in microcapsules resulting in decreased functionality has been one of obstacles of the success of ose gel layer on the microparticles.
